Clinical trial of cancer vaccine using NY-ESO-1/CpG

使用 NY-ESO-1/CpG 进行癌症疫苗的临床试验

• 批准号: 18390356
• 负责人: KONDO Satoshi
• 金额: $ 10.67万
• 依托单位: Hokkaido University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18390356/
• 关键词: cancer; vaccine; tumor antigen; NY-ESO-1; CpG; 巖免疫療法; CD4+T細胞; CD8+T細胞; 臨床試験; 進行再発癌; 癌ワクチン

The purpose of this study is to clarify the status of tumor antigen NY-ESO-1 expression in patients with cancer and the safety of cancer vaccination for patients with NY-ESO-1 expressing tumor. Initially, we constructed a positive control and a negative control for immunohistochemistry (IHC) to screen gene expression of NY-ESO-1. RT-PCR identified that HEC46 was NY-ESO-1 positive and TE8 negative. These cell lines were implanted into SCID mice subcutaneously and the tumors were resected. Paraffin embedded sections were made and appropriate condition of IHC was confirmed. NY-ESO-1 expression was analyzed by. IHC in 122 patients with esophageal squamous cell carcinoma (ESCC). The prognosis of patients with advanced ESCC expressing NY-ESO-1 was significantly better than that of patients with NY-ESO-1 negative tumor. Moreover, NY-ESO-1 expression was significantly correlated to the number of infiltrating CD4+T cells and CD8+T cells. Therefore, NY-ESO-1 expression would induce anti-tumor immunity of the host in patients with ESCC. Subsequently, clinical trial of cancer vaccination using NY-ESO-1 and CpG was performed. The purpose of the trial was to clarify the safety of the therapy. A patient with breast cancer was entered this trial and vaccinations were tried tree times. No side effect was observed and no clinical benefit was confirmed.

这项研究的目的是阐明癌症患者肿瘤抗原NY-ESO-1表达的状态以及ny-Eso-1表达肿瘤患者的癌症疫苗接种的安全性。最初，我们构建了一个阳性对照和免疫组织化学（IHC）的阴性对照，以筛选NY-ESO-1的基因表达。 RT-PCR确定HEC46为NY-ESO-1阳性，TE8为阴性。这些细胞系皮下植入SCID小鼠，并切除肿瘤。制作了石蜡嵌入的部分，并确认了适当的IHC条件。通过分析了NY-ESO-1的表达。 IHC在122例食管鳞状细胞癌（ESCC）患者中。表达NY-ESO-1的晚期ESCC患者的预后明显好于NY-ESO-1阴性肿瘤患者。此外，NY-ESO-1表达与浸润的CD4+T细胞和CD8+T细胞的数量显着相关。因此，NY-ESO-1表达将诱导ESCC患者宿主的抗肿瘤免疫。随后，使用NY-ESO-1和CPG对癌症疫苗接种的临床试验。该试验的目的是阐明治疗的安全性。该试验进入了乳腺癌患者，并尝试了疫苗接种。未观察到副作用，也没有确认临床益处。

项目成果

Resection of lung metastasis from gallbladder carcinoma: immunohistoch emistry of RCASI and CD8+T cells in primary and metastatic tumors

胆囊癌肺转移切除：原发性和转移性肿瘤中 RCASI 和 CD8 T 细胞的免疫组化发射

• 发表时间: 2006
• 期刊: Cancer Letters 237
• 作者: Taro Oshikiri;Takayuki Morita;etc
• 通讯作者: etc

Espression profiling of MMPs, TIMPs, and RECK in human lung cancer.

人类肺癌中 MMP、TIMP 和 RECK 的表达谱。

• 发表时间: 2006
• 作者: Fukumitsu K;Ikai I;et. al.;恒富亮一;竹本法弘
• 通讯作者: 竹本法弘

Infiltrating regulatory T cell numbers is not a factor to patient's survival in oesophageal squamous cell carcinoma

浸润性调节性 T 细胞数量并不是食管鳞状细胞癌患者生存的一个因素

• 发表时间: 2008
• 期刊: Br j Cancer 98(7)
• 作者: Yoshioka T;M Miyamoto;Y etc
• 通讯作者: Y etc

Phosphorylation and Activation of CDCA8 by AURKB Plays a Significant Role in Human Lung Carcinogenesis

AURKB 磷酸化和激活 CDCA8 在人类肺癌发生中发挥重要作用

• 发表时间: 2007
• 作者: 高橋洋子(慶應義塾大学医学部一般・消化器外科);神野浩光;麻賀創太;坂田道生;上田政和;北川雄光;Hayama S
• 通讯作者: Hayama S

Identification of an Oncogenic WD-repeat -containing Testicular protein which was Activated in Lung and Esophageal Cancer

肺癌和食道癌中激活的含有致癌 WD 重复序列的睾丸蛋白的鉴定

• 发表时间: 2007
• 作者: Li WQ;Kawakami K;et al.;佐藤暢人
• 通讯作者: 佐藤暢人